1 domain / 2 areas / 1 specialization
Ambria Capital
Data updated
Ambria Capital is a venture capital firm that focuses on early-stage companies in mental health and technology, with a stated current emphasis on psychedelic therapies and technologies. The firm says it invests its own money and can fund companies at any stage and in any amount, and its leadership includes founder Michael Sobeck and managing partner Cody Shandraw.
The firm matters in the psychedelic ecosystem because it explicitly backs psychedelic therapies and technologies and describes itself as one of the more active investors in the space. Its website and related public materials point to investments and support across the industry, including companies such as Wesana Health, and it has also been associated with broader neurowellness and brain-health investing through Phyto Partners.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Ambria Capital presents itself as a hands-on venture investor using proprietary capital to back early-stage frontier companies, especially in mental health, psychedelics, and related technologies. The firm’s public messaging emphasizes pre-Series A orientation, long-duration support, and a thesis around psychedelic-assisted therapies, diagnostic tools, and technology-enabled mental healthcare. Public materials also indicate the team has backed a large number of companies and has been active in the commercial psychedelics ecosystem.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- Founded
- 2018
- HQ
- Southern California / San Diego area, United States
- Website
- Visit